EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Role of oral tetracyclines in preventing acneiform rash in patients with non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review

R Sousa, B Vieira Granja, S Magina

Actas Dermo-Sifiliográficas · 2025

DOI: 10.1016/j.ad.2025.104583 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Actas Dermo-Sifiliográficas, 2025. Verfasst von R Sousa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: up201704666@up.pt. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, ErbB Receptors, Tetracyclines. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the current first-line therapy for non-small cell lung cancer (NSCLC). Acneiform rash is a common adverse effect of this treatment, leading to treatment interruption and affecting the patients' quality of life. METHODS: We conducted a systematic review to assess the role of oral tetracyclines in the prevention of acneiform rash on patients with NSCLC on EGFR TKIs. We conducted a search across Pubmed, Web of Science and Cochrane databases in January 2025. Studies were included if they evaluated prophylactic treatment with oral tetracyclines for acneiform rash in patients with non-small cell lung cancer initiating concomitant epidermal growth factor receptor tyrosine kinase inhibitor therapy. RESULTS: Two of the 7 selected studies found tetracyclines to reduce all-grade rash - doxycycline (74.2% to 57.2%) and tetracycline (75.6-44.5%; p=0.046). Two found tetracyclines did not reduce all-grade rash but were effective in reducing high-grade rash - doxycycline (19-4%; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProtein Kinase InhibitorsErbB ReceptorsTetracyclinesLung NeoplasmsAcneiform EruptionsDrug EruptionsHumansAdministration, OralTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Acneiform rashEpidermal growth factor (EGFR)Non-small cell lung cancer (NSCLC)Oral tetracyclinesProphylactic treatmentTyrosine kinase inhibitors (TKIs)

Substanzen

Protein Kinase InhibitorsErbB ReceptorsTetracyclinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: up201704666@up.pt.
  • Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal; Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal.

Zitieren

APA

Sousa, R., Vieira Granja, B., & Magina, S. (2025). Role of oral tetracyclines in preventing acneiform rash in patients with non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.104583

Vancouver

Sousa R, Vieira Granja B, Magina S. Role of oral tetracyclines in preventing acneiform rash in patients with non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review. Actas Dermo-Sifiliográficas. 2025. doi:10.1016/j.ad.2025.104583

BibTeX
@article{Sousa2025,
  author = {Sousa, R and Vieira Granja, B and Magina, S},
  title = {Role of oral tetracyclines in preventing acneiform rash in patients with non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2025},
  doi = {10.1016/j.ad.2025.104583}
}
Kostenlos starten →